Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Olink Bioscience Introduces a 92-protein Biomarker Panel

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Proseek® Multiplex Inflammation I 96x96 for inflammatory diseases.

Olink Bioscience has launched Proseek® Multiplex Inflammation I 96x96, a new protein biomarker panel that targets a wide range of inflammatory diseases. This panel complements the existing panels directed against Oncology and Cardiovascular diseases in a growing collection.

Proseek Multiplex Inflammation I 96x96 will be an important tool in the search for new multivariate protein expression patterns that could serve as biomarkers to improve prediction and prognosis of inflammatory diseases, as well as discovery of new drug targets.

Inflammatory mechanisms are involved in many types of diseases where the immune system creates a chronic inflammation often resulting in functional impairment of organs. Rheumatoid arthritis, multiple sclerosis, psoriasis, irritable bowel diseases, and asthma are examples of such diseases.

The inflammatory response also plays a major role in other diseases such as cardiovascular disorders, cancer, diabetes and Alzheimer’s disease. Chronic immune system disorders affect millions of people every year, and there is a great unmet need in predicting the efficacy of treatment options at individual level. It is crucial to find new biomarkers to meet these needs in personalized medicine but also for better healthcare in general through improving diagnostic and prognostic tools.

“With the launch of our next exciting multiplex immunoassay panel we are another step closer to the vision of identifying protein profiles that will change the way we prevent, diagnose and treat diseases. Proseek Multiplex makes anyone with access to biological material able to screen for protein biomarker profiles in an exceptionally efficient way.” says Andrea Ballagi, Chief Operating Officer at Olink Bioscience.

Proseek Multiplex Inflammation I 96x96 is a high throughput multiplex immunoassay that efficiently measures 92 inflammation-related proteins across 96 samples (including controls) simultaneously in only one microliter of serum or plasma. When used in combination with Fluidigm’s Biomark TM HD system, a high throughput real-time PCR platform, it enables researchers to analyze thousands of samples per week, which greatly accelerates the speed of discovery of new protein biomarkers.

“We are very pleased with the initial results obtained with Proseek Multiplex Inflammation I 96x96. We have already found several interesting biomarker candidates and we will now extend our study to compare the results with other available panels. Proseek Multiplex Inflammation I 96x96 is certainly a promising tool for future use in rheumatoid arthritis” say Professor Lars Klareskog and Assoc.Prof. Anca Catrina, Rheumatology clinic and research unit, Karolinska University Hospital and Karolinska Institutet.

The Proseek Multiplex Inflammation I 96x96 panel comprises established inflammatory markers as well as a few proteins with great potential to become new biomarkers for inflammatory disorders. The content of the panel has been designed in close collaboration with experts in various inflammatory disease fields such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, neuro inflammation, and respiratory diseases. The panel is therefore well suited to elucidating protein expression profiles in clinically relevant samples. Proseek Multiplex Inflammation I 96x96 is the third panel from Olink Bioscience.

Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!